Is LENZ Therapeutics, Inc. (LENZ) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for LENZ Therapeutics, Inc. (LENZ) using a discounted cash flow (DCF) model and long-term earnings assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is LENZ a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether LENZ trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

LENZ

LENZ Therapeutics, Inc.

$11.49

-0.23

(-1.96%)

Exchange:
Market Cap:	359.522M
Shares Outstanding:	8.297M

Overview

Earnings

Financials

Valuation

Chart

About The Company

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Click to read more…